Navigation Links
MiMedx Is Issued Four Additional U.S. Patents For Placental Tissue Grafts
Date:2/11/2013

ic tissue is very gentle to the tissue, and allows us to preserve the critical wound healing characteristics that are inherent in the amniotic tissue, and this yields an allograft with remarkable healing capabilities. This process does not decellularize the tissue, but rather retains those growth factors and cytokines that are critical to healing."

The MiMedx allografts produced from the Company's proprietary PURION® Process for amniotic membrane tissue can be stored at room temperature for five years without the need for refrigeration or freezing.  The grafts can be utilized right out of the package without a complicated thawing process.  These critical qualities of the MiMedx allografts allow hospitals, clinics and surgeons to effectively manage their inventory of allografts.

About the Company
MiMedx® is an integrated developer, manufacturer and marketer of patent protected regenerative biomaterial products and bioimplants processed from human amniotic membrane. "Innovations in Regenerative Biomaterials" is the framework behind our mission to give physicians products and tissues to help the body heal itself. Our biomaterial platform technologies include the device technologies HydroFix® and CollaFix™, and our tissue technologies, AmnioFix® and EpiFix®. Our tissue technologies are processed from human amniotic membrane that is derived from the donated placentas. Through our donor program, mothers delivering full-term Caesarean section births can elect in advance of delivery to donate the placenta in lieu of having it discarded as medical waste. We process the human amniotic membrane utilizing our proprietary Purion® Process, to produce a safe, effective and minimally manipulated implant for homologous use. MiMedx® is the leading supplier of amniotic tissue, having supplied over 120,000 allografts to date to distributors and OEMs for application in the Wound care, Surgical, Sports Medicine,
'/>"/>

SOURCE MiMedx Group, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. MiMedx Group, Inc. to Present at the 6th Annual Canaccord Genuity Cardiovascular, Aesthetics and Metabolic Disorders Conference
2. MiMedx Group Completes $5,000,000 Private Placement
3. MiMedx Group, Inc. Receives CE Certification for Its CollaFix™ Surgical Mesh CD
4. MiMedx to Present at American Academy of Orthopaedic Surgeons Annual Meeting
5. MiMedx Group Announces 2011 Results
6. MiMedx Signs Agreement with Systagenix for Global Distribution of EpiFix®
7. MiMedx Exceeds Revenue Goal for First Quarter of 2012
8. MiMedx Group Announces Record First Quarter Results
9. MiMedx Group, Inc. Announces Release Date for 2012 Second Quarter Results
10. MiMedx Group Announces Record Second Quarter Results
11. MiMedx Group to Present at the Canaccord Genuity Annual Growth Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... The report “Pharmacy Automation Systems ... and Labeling Systems, Table-top Counters) by End-user (Inpatient ... & Trends to 2019” analyzes and studies the ... America, Europe, Asia-Pacific, and the Rest of the ... 30 figures spread through 300 pages and in-depth ...
(Date:10/20/2014)... 20, 2014 Asterias Biotherapeutics, Inc. (NYSE ... signed a Notice of Grant Award (NGA) with ... October 1, 2014.  The NGA provides for the ... release of additional grant funds pursuant to the ... clinical development of Asterias, product, AST-OPC1. The grant ...
(Date:10/20/2014)...  GenVec, Inc. (NASDAQ: GNVC ) today announced ... its board of directors effective on October 24, 2014.   Dr. ... as its chairman from June 2006 to November 2013.  During ... Governance and Audit Committees of the board.  ... dedicated service to GenVec, and its stockholders," said Wayne ...
(Date:10/20/2014)... Rochelle, Virginia (PRWEB) October 20, 2014 ... of NDA Partners LLC, announced today that Ellen ... and legal support for the pharmaceutical industry, has ... and manager of its legal services practice. ... reports and expert witness and testimony, to top ...
Breaking Biology Technology:Pharmacy Automation Systems Market worth $4,566.2 Million by 2019 - New Research Report by MarketsandMarkets 2Pharmacy Automation Systems Market worth $4,566.2 Million by 2019 - New Research Report by MarketsandMarkets 3Pharmacy Automation Systems Market worth $4,566.2 Million by 2019 - New Research Report by MarketsandMarkets 4Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 2Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 3Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 4Zola P. Horovitz To Retire From GenVec Board 2NDA Partners Appoints Ellen Teplitzky, JD as Director of its Legal Services Practice 2
... , , , BETHLEHEM, Pa., ... , (Logo: http://www.newscom.com/cgi-bin/prnh/200 8 1022 / ... two Lehigh Valley healthcare leaders, Good S h epherd Rehabilitation ... nc. (B. Braun), which are combining their knowledge, expertise and innovative technology ...
... , , , TUSTIN, ... today announced that it will release its financial results for the first ... EDT and will host a conference call and webcast to discuss the ... Peregrine,s senior management will discuss financial results for the first ...
... , , SEATTLE, Aug. 27 ... Company will hold an Analyst Day on Thursday, September 24, 2009 beginning ... audio webcast of the presentation will be accessible through the Investor Relations ... to listen to the live webcast, it will be archived on the ...
Cached Biology Technology:Two Lehigh Valley Healthcare Leaders Collaborate to Deliver Safer, High-Quality Care to the Community 2Two Lehigh Valley Healthcare Leaders Collaborate to Deliver Safer, High-Quality Care to the Community 3Two Lehigh Valley Healthcare Leaders Collaborate to Deliver Safer, High-Quality Care to the Community 4Peregrine Pharmaceuticals to Report First Quarter FY 2010 Financial Results 2
(Date:10/22/2014)... BEDFORD, Mass., Oct. 21, 2014 Aware, Inc. (NASDAQ: ... and services, today reported financial results for its third quarter ... quarter of 2014 was $6.0 million, an increase of 40% ... Operating income in the third quarter of 2014 was $4.1 ... 2013. Higher operating income in the current three month period ...
(Date:10/18/2014)... referred for evaluation of suspected genetic conditions, whole-exome ... percent, including detection of a number of rare ... according to a study appearing in JAMA ... with the American Society of Human Genetics annual ... coding regions of thousands of genes simultaneously using ...
(Date:10/17/2014)... German . ... in order to reproduce? And why are there two sexes ... latest issue of the research journal Molecular Human Reproduction ... Ramm from Bielefeld University Bielefeld has compiled this special issue ... a female to copulate with several males in quick succession ...
Breaking Biology News(10 mins):Aware, Inc. Reports Third Quarter 2014 Financial Results 2Aware, Inc. Reports Third Quarter 2014 Financial Results 3Aware, Inc. Reports Third Quarter 2014 Financial Results 4Aware, Inc. Reports Third Quarter 2014 Financial Results 5Aware, Inc. Reports Third Quarter 2014 Financial Results 6Aware, Inc. Reports Third Quarter 2014 Financial Results 7Whole-exome sequencing shows potential as diagnostic tool 2Sperm wars 2
... for spiders, it can be a matter of life or ... potentially cannibalistic females that he is a suitable mate and ... Cincinnati shows that male wolf spiders are "leaving" little to ... mate. To improve the chances of the right message ...
... A new company has been launched to commercialise ... Strathclyde in Glasgow, for tackling bacterial infection and ... Phage Limited has been established to develop products ... prevention of infection and bacterial contamination in medicine, ...
... standard intestinal examination for diagnosing and monitoring Crohn,s disease. It ... with a camera is passed into the large intestine. MRI ... the course of the disease and how it is responding ... the academic world to develop an objective, quantitative method for ...
Cached Biology News:Spiders adjust courtship signals for maximum effect 2Spiders adjust courtship signals for maximum effect 3Spin-out to apply new technology for tackling infection 2Spin-out to apply new technology for tackling infection 3EU grant for better monitoring of Crohn's disease using MRI 2EU grant for better monitoring of Crohn's disease using MRI 3
... The active ingredient in Molecular Probes. ... appears to act as a free ... emission. Our original SlowFade formulation (S-2828) ... rate of fluorescein to almost zero ...
... IRsolution software provides quick and easy ... functions with Windows-based control. The software ... and FDA 21 CFR Part 11 regulations, ... of measurement. IRsolutions versatility enables use ...
b6-2A12...
... reagents for immune complex disruption (ICD) of ... using a combination of low pH and ... transferred to microplate wells which are coated ... to HIV-1 p24. The immobilized monoclonal antibody ...
Biology Products: